Comparison of the immunogenicity of Cervarix^®and Gardasil^®human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults

Abstract excerpt

Individuals infected with human immunodeficiency virus (HIV) have excess risk of developing human papillomavirus (HPV)-related disease. A substantial fraction of HPV-associated cancers is caused by HPV serotypes not included in the currently available vaccines. Among healthy women, both Cervarix(®) (HPV-16/18, GlaxoSmithKline Biologicals, GSK) and Gardasil(®) (HPV-6/11/16/18, Merck) have demonstrated partial...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cervical Cancer and HPV Research
• Share to Genital Health and Disease
• Share to Hepatitis B Virus Studies